Aethansulfonsaeure-<2-methoxy-anilid> | 57616-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Aethansulfonsaeure-<2-methoxy-anilid>
• 英文别名: Aethansulfonsaeure-(2-methoxy-anilid)；Ethanesulfonamide, N-(2-methoxyphenyl)-；N-(2-methoxyphenyl)ethanesulfonamide
• CAS: 57616-34-9
• 化学式: C₉H₁₃NO₃S
• mdl: MFCD01327721
• 分子量: 215.273
• InChiKey: VHJYUXYQEDYZDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Aethansulfonsaeure-<2-methoxy-anilid> 在 溴 作用下， 生成 ethanesulfonic acid-(3,6-dibromo-2-methoxy-anilide)
  参考文献：
  名称：

  Koszowa, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3799,3801;engl.Ausg.S.3761

  摘要：

  DOI：
• 作为产物：
  描述：

  邻甲氧基苯胺 、 乙基磺酰氯 以75%的产率得到
  参考文献：
  名称：

  STARODUBTSEVA M. P.; SKRYPNIK YU. G.; VIZGERT R. B, VOPR. XIMII I XIM. TEXNOL., 1977, HO 49, 3-8

  摘要：

  DOI：

文献信息

• Carboxamide Compounds and Their Use
  申请人：Ben-Zeev Efrat

  公开号：US20100324035A1

  公开（公告）日：2010-12-23

  Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

  化学因子受体拮抗剂，特别是化合物式(I-A)的拮抗剂，作为化学因子CCR2受体的拮抗剂，包括其药物组合物和用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。
• CARBOXAMIDE COMPOUNDS AND THEIR USE
  申请人：Lin Jian

  公开号：US20100210633A1

  公开（公告）日：2010-08-19

  Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

  本文介绍了化学因子受体拮抗剂，特别是公式(I)化合物，它们作为化学因子CCR2受体的拮抗剂，包括制药组合物及其用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。
• DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS
  申请人：Jones Simon

  公开号：US20100286136A1

  公开（公告）日：2010-11-11

  The invention provides methods of using dihydronaphthyridinyl and related compounds to treat opthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.

  本发明提供了使用二氢萘啶和相关化合物治疗眼科疾病的方法，例如湿性年龄相关性黄斑变性，糖尿病视网膜病变和高度近视。还提供了制备二氢萘啶和相关化合物的药物组合物和合成方法。
• Koszowa, Zhurnal Obshchei Khimii, 1958, vol. 28, p. 1573,1575;engl.Ausg.S.1623,1625
  作者：Koszowa

  DOI：——

  日期：——
• Non-Peptidic Inhibitors of AKAP/PKA Interaction
  申请人：Klussmann Enno

  公开号：US20090176773A1

  公开（公告）日：2009-07-09

  The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism that comprises said non-peptidic compounds or recognition molecules directed to said compounds, such as e.g. antibodies or chelating agents. The invention also relates to a pharmaceutical agent, especially for use in the treatment of diseases that are associated with a disturbance of the cAMP signal path, especially insipid diabetes, hypertonia, pancreatic diabetes, duodenal ulcer, asthma, heart failure, obesity, AIDS, edema, hepatic cirrhosis, schizophrenia and others. The invention also relates to the use of the inventive molecules.